| Imagery Source: Wikimedia Commons / LittleT889 |
| Information Source: AbbVie |
- Reports Third-Quarter Diluted EPS of $0.10 on a GAAP Basis, a Decrease of 88.6 Per cent; Adjusted Diluted EPS of $1.86, a Decrease of 38.0 Per cent; These Results Include Unfavourable Impact of $1.50 Per Share Related to Acquired IPR&D and Milestones Expense
|
- Delivers Third-Quarter Net Revenues of $15.776 Billion, an Increase of 9.Per cent on a Reported Basis or 8.4 per cent on an Operational Basis
|
- Third-Quarter Global Net Revenues from the Immunology Portfolio Were $7.885 Billion, an Increase of 11.9 Per cent on a Reported Basis, or 11.2 Per cent on an Operational Basis; Global Skyrizi Net Revenues Were $4.708 Billion; Global Rinvoq Net Revenues Were $2.184 Billion; Global Humira Net Revenues Were $993 Million.n
|
- Third-Quarter Global Net Revenues from the Neuroscience Portfolio Were $2.841 Billion, an Increase of 20.Per cent on a Reported Basis, or 19.6 Per cent on an Operational Basis; Global Vraylar Net Revenues Were $934 Million; Global Botox Therapeutic Net Revenues Were $985 Million; Combined Global Ubrelvy and Qulipta Net Revenues Were $642 Million.n
|
- Third-Quarter Global Net Revenues from the Oncology Portfolio Were $1.682 Billion, a Decrease of 0.Per cent on a Reported Basis, or 1.3 Per cent on an Operational Basis; Global Imbruvica Net Revenues Were $706 Million; Global Venclexta Net Revenues Were $726 Million; Global Elahere Net Revenues Were $170 Milli.
|
- Third-Quarter Global Net Revenues from the Aesthetics Portfolio Were $1.193 Billion, a Decrease of 3.7 Per cent on a Reported Basis, or 4.2 Per cent on an Operational Basis; Global Botox Cosmetic Net Revenues Were $637 Million; Global Juvederm Net Revenues Were $253 Milli.
|
- Raises 2025 Adjusted Diluted EPS Guidance Range from $10.38 - $10.58 to $10.61 - $10.65, which includes an unfavourable impact of $2.05 Per Share Related to acquired IPR&D and Milestones Expense Incurred Year-To-Date Through the Third Quarter 2025
|
- Announces 2026 Dividend Increase of 5.5 Per cent, Beginning with Dividend Payable in February 2026
|
| AbbVie (NYSE: ABBV) announced financial results for the third quarter ended September 30, 2025. |
| "AbbVie continues to deliver outstanding results, with significant momentum across key areas of our portfolio. We are also making great progress advancing our pipeline and investing in innovation to support AbbVie's long-term growth," said Robert A. Michael, chairman and chief executive officer, AbbVie. "Based upon the strength of our business and its promising outlook, we are once again raising our quarterly cash dividend." |
| Third-Quarter Results |
- Worldwide net revenues were $15.776 billion, an increase of 9.1 per cent on a reported basis, or 8.4 per cent on an operational basis.
Global net revenues from the immunology portfolio were $7.885 billion, an increase of 11.9 per cent on a reported basis, or 11 per cent on an operational basis.
|
-
- Global Skyrizi net revenues were $4.708 billion, an increase of 4per cent on a reported basis, or 46.0 per cent on an operational basis.
|
-
- Global Rinvoq net revenues were $2.184 billion, an increase of 35.3 per cent on a reported basis, or 34.1 per cent on an operational basis.
|
- Global Humira net revenues were $993 million, a decrease of 55.4 per cent on a reported basis, or 55.7 per cent on an operational basis.
Global net revenues from the neuroscience portfolio were $2.841 billion, an increase of 20.2 per cent on a reported basis, or 19 per cent on an operational basis.
|
-
- Global Vraylar net revenues were $934 million, an increase of 6.7 per cent.
|
-
- Global Botox Therapeutic net revenues were $985 million, an increase of 16.1 per cent on a reported basis, or 15.8 per cent on an operational basis.
|
-
- Global Ubrelvy net revenues were $354 million, an increase of 31.5 per cent.
|
- Global Qulipta net revenues were $288 million, an increase of 64.1 per cent on a reported basis, or 63.1 per cent on an operational basis.
Global net revenues from the oncology portfolio were $1.682 billion, a decrease of 0 per cent on a reported basis, or 1.3 per cent on an operational basis.
|
-
- Global Imbruvica net revenues were $706 million, a decrease of 14.8 per cent.
|
-
- Global Venclexta net revenues were $726 million, an increase of 7.1 per cent on a reported basis, or 4.9 per cent on an operational basis.
|
- Global Elahere net revenues were $170 million, an increase of 23.3 per cent on a reported basis, or 22.4 per cent on an operational basis.
Global net revenues from the aesthetics portfolio were $1.193 billion, a decrease of 3.7 per cent on a reported basis, or 4.2 per cent on an operational basis.
|
-
- Global Botox Cosmetic net revenues were $637 million, a decrease of 4.9 per cent on a reported basis, or 5.4 per cent on an operational basis.
|
- Global Juvederm net revenues were $253 million, a decrease of 2.2 per cent on a reported basis, or 3.2 per cent on an operational basis.
On a GAAP basis, gross margin in the third quarter was 66.4 per cent. The adjusted gross margin was 83.9 per cent.
On a GAAP basis, selling, general and administrative (SG&A) expense was 22.6 per cent of net revenues. The adjusted SG&A expense was 21 per cent of net revenues.
- On a GAAP basis, research and development (R&D) expense was 14.7 per cent of net revenues. The adjusted R&D expense was 14.3 per cent of net revenues.
Acquired IPR&D and milestones expense was 17.0 per cent of net revenues.
On a GAAP basis, operating margin in the third quarter was 12 per cent. The adjusted operating margin was 3per cent.
- Net interest expense was $667 million.
On a GAAP basis, the tax rate in the quarter was per cent. The adjusted tax rate was 24.5 per cent.
- Diluted earnings per share (EPS) in the third quarter were $0.10 on a GAAP basis. Adjusted diluted EPS, excluding specified items, was $1.86. These results include an unfavourable impact $1.50 per share related to acquired IPR&D and milestones expense.
|
| Note: "Operational" comparisons are presented at constant currency rates that reflect comparative local currency net revenues at the prior year's foreign exchange rates. |
| Recent Events |
- AbbVie announced the U.S. Food and Drug Administration (FDA) approval of a supplemental New Drug Application (sNDA) that updates the indication statement for Rinvoq (upadacitinib) for the treatment of adults with moderately to severely active ulcerative colitis (UC) and moderately to severely active Crohn's disease (CD). The updated indication statement allows the use of Rinvoq before the use of tumour necrosis factor (TNF) blocking agents in patients for whom use of these treatments is clinically inadvisable and who have received at least one approved systemic therapy.
|
- AbbVie announced positive topline results from the second of two pivotal studies of the Phase 3 UP-AA clinical program evaluating the safety and efficacy of Rinvoq in adult and adolescent patients with severe alopecia areata (AA). In the study, Rinvoq achieved the primary endpoint, demonstrating that 45.2% and 55.0% of patients with severe AA treated with Rinvoq 15 mg and 30 mg, respectively, reached 80% or more scalp hair coverage at week 24 as defined by the severity of alopecia tool (SALT) score ≤ 20. Key secondary endpoints, including improvements in eyebrows and eyelashes, as well as the percentage of subjects with 90% or more scalp coverage (SALT ≤ 10) and complete scalp hair coverage (SALT=0) at week 24, were also met. Rinvoq's safety profile in AA was generally consistent with that in approved indications, and no new safety signals were identified in this study.
|
- AbbVie announced topline results from two replicate Phase 3 studies evaluating the efficacy and safety of Rinvoq 15 mg in adult and adolescent patients living with non-segmental vitiligo (NSV). In the studies, Rinvoq achieved the co-primary endpoints of 50% reduction in total Vitiligo Area Scoring Index (T-VASI 50) from baseline and 75% reduction in Facial Vitiligo Area Scoring Index (F-VASI 75) from baseline at week 48. Additionally, across both studies, statistically significant differences were observed with Rinvoq versus placebo in key ranked secondary endpoints, including F-VASI 50 at week 48. The safety profile of Rinvoq in both studies was generally consistent with that observed in approved indications.
|
- AbbVie announced positive topline results from the Phase 3b/4 head-to-head SELECT-SWITCH study evaluating the efficacy and safety of Rinvoq compared to Humira (adalimumab) in adult patients with moderate to severe rheumatoid arthritis (RA), who had an inadequate response or intolerance to a single TNF inhibitor other than Humira. In the study, Rinvoq demonstrated superiority versus Humira in the primary endpoint of achieving low disease activity and demonstrated superiority for additional ranked secondary endpoints at week 12. Rinvoq's safety profile was consistent with previously reported studies, with no new safety risks identified.
|
- AbbVie announced that it completed its acquisition of Capstan Therapeutics. The acquisition adds a potential first-in-class in vivo targeted lipid nanoparticle (tLNP) anti-CD19 CAR-T therapy candidate for B cell-mediated autoimmune diseases, as well as a proprietary tLNP platform designed to deliver RNA payloads, such as mRNA, capable of engineering specific cell types in vivo.
|
- AbbVie announced that it submitted a New Drug Application (NDA) to the FDA for tavapadon, a novel selective dopamine D1/D5 receptor partial agonist for the treatment of Parkinson's disease (PD). The submission is supported by data from the Phase 3 TEMPO program, which demonstrated symptomatic improvement across the PD spectrum. If approved, tavapadon will enhance AbbVie's position in PD by providing patients with a once daily oral treatment option.
AbbVie announced positive topline results from the Phase 2 ELATE trial evaluating the safety and efficacy of Botox (onabotulinumtoxinA) for the treatment of upper limb essential tremor. Botox met the primary endpoint in the Phase 2 trial, demonstrating a statistically significant improvement from baseline in the Tremor Disability Scale-Revised (TREDS-R) total unilateral score compared to placebo. The trial also met all six secondary endpoints. Results from safety analyses were generally consistent with the well-established safety profile of Botox.
|
- AbbVie announced that it completed its acquisition of Gilgamesh Pharmaceuticals' lead investigational candidate, bretisilocin. Bretisilocin is a novel, short-acting serotonin (5-HT)2A receptor agonist and 5-HT releaser psychedelic compound with best-in-class potential, which is currently in Phase 2 clinical development for the treatment of patients with moderate-to-severe major depressive disorder (MDD). Positive topline results from a Phase 2a study of bretisilocin in MDD were previously announced, demonstrating a clinically impactful and statistically significant reduction in severity of depressive symptoms versus a low-dose active comparator, as measured by the Montgomery-Ã…sberg Depression Rating Scale (MADRS) total score.
|
- AbbVie announced submission of a new Biologics License Application (BLA) to the FDA for approval of pivekimab sunirine (PVEK), an investigational antibody-drug conjugate (ADC), for treatment of blastic plasmacytoid dendritic cell neoplasm (BPDCN). The submission is based on data from the Phase 1/2 CADENZA trial, a global study evaluating the safety and efficacy of PVEK in BPDCN. BPDCN is a rare and aggressive blood cancer with a significant need for innovative treatment options for both newly diagnosed patients and those whose prior treatments have resulted in relapsed or refractory (R/R) disease.
|
- At the European Society for Medical Oncology (ESMO) Congress, AbbVie presented new data from its ADC portfolio in patients with difficult-to-treat tumour types. Highlights included three oral presentations for Temab-A (telisotuzumab adizutecan) as a monotherapy or in combination across advanced, solid tumours, as well as a new analysis of ABBV-706 for the treatment of R/R small cell lung cancer (SCLC).
|
- At the Society of Hematologic Oncology (SOHO) Annual Meeting, AbbVie announced updated results from the Phase 2 EPCORE NHL-6 trial evaluating the feasibility of dosing and monitoring patients in the outpatient setting for the first full dose of Epkinly (epcoritamab) monotherapy in adult patients with R/R diffuse large B-cell lymphoma (DLBCL) who have received at least one prior line of systemic therapy. Results from the study demonstrated that the incidence and severity of cytokine release syndrome (CRS) and immune cell-associated neurotoxicity syndrome (ICANS) following treatment with epcoritamab were consistent with previous epcoritamab studies in R/R DLBCL.
|
- AbbVie announced plans to launch Elahere (mirvetuximab soravtansine-gynx) in the U.K. at a list price equal to the U.S., reflecting the advanced innovation and value of the treatment for adult patients with folate receptor-alpha (FRα) positive, platinum-resistant high-grade serous epithelial ovarian, fallopian tube, or primary peritoneal cancer who have received one to three prior systemic treatment regimens. AbbVie is committed to ensuring that developed nations fully recognise the value of our medicines in improving patient outcomes, consistent with the level of recognition in the U.S.
|
- Allergan Aesthetics announced several marketing initiatives, which include a new national, multichannel, campaign highlighting Botox Cosmetic's (onabotulinumtoxinA) market leadership, legacy and real-world patient experiences; the launch of a consumer education campaign that is aimed at providing clear, factual information about hyaluronic acid (HA) injectable fillers and the natural-looking results they can achieve; and the launch of SkinVive by Juvederm into 35 new markets.
|
- AbbVie announced it broke ground on a $195 million state-of-the-art active pharmaceutical ingredient (API) facility that will manufacture immunology, oncology and neuroscience medicines. This North Chicago, Ill. facility is expected to be fully operational and serving patients by 2027. The company also announced the start of construction on a $70 million expansion at its AbbVie Bioresearch Centre) in Worcester, Mass., which will increase biologics manufacturing for immunology and oncology medicines. These projects are part of AbbVie's previously announced commitment to invest more than $10 billion of capital in the U.S. to broadly support innovation and expand critical manufacturing capabilities and capacity.
|
| Full-Year 2025 Outlook |
| AbbVie is raising its adjusted diluted EPS guidance for the full year 2025 from $10.38 - $10.58 to $10.61 - $10.65, which includes an unfavourable impact of $2.05 per share related to acquired IPR&D and milestones expense incurred year-to-date through the third quarter 2025. The company's 2025 adjusted diluted EPS guidance excludes any impact from acquired IPR&D and milestones that may be incurred beyond the third quarter of 2025, as both cannot be reliably forecasted. |
| Company Declares Dividend Increase of 5.5 Per cent. |
| AbbVie is announcing today that its board of directors declared an increase in the company's quarterly cash dividend from $1.64 per share to $1.73 per share beginning with the dividend payable on February 17, 2026, to shareholders of record as of January 16, 2026. This reflects an increase of approximately 5.5perr per cent, continuing AbbVie's strong commitment to returning cash to shareholders through a growing dividend. Since the company's inception in 2013, AbbVie has increased its quarterly dividend by more than 330 per cent. AbbVie is a member of the S&P Dividend Aristocrats Index, which tracks companies that have annually increased their dividend for at least 25 consecutive years. |
| About AbbVie |
| AbbVie's mission is to discover and deliver innovative medicines that solve serious health issues today and address the medical challenges of tomorrow. We strive to have a remarkable impact on people's lives across several key therapeutic areas: immunology, neuroscience, oncology, and eye care- and products and services across our Allergan Aesthetics portfolio. For more information about AbbVie, please visit us at www.abbvie.com. Follow @abbvie on X (formerly Twitter), Facebook, Instagram, YouTube or LinkedIn. |
| For the full document, click the link below |
| AbbVie |
| Stay ahead of the curve! Subscribe to InsidEntity for daily updates on all your favourite companies. |
